AMEX
0.18USD
+0.00 (+2.46%)
We have scored 9 news catalysts on VolitionRX Ltd (VNRX) over the past 12 months. The biggest single-day move next to one of them came Jan 8, 2026, when VNRX closed +24.3%: “VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats”. Coverage across the window leans positive (average ticker sentiment +0.60). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.2M
P/E
—
EPS
—
Beta
1.17
52W range
0.1564-9.6
Day range
0.16–0.19
Open
0.19
Prev close
0.18
Volume
3.5M
Avg volume
6M
Dividend
0.00
IPO
2012-03-02
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about VolitionRX Ltd — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for VNRX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
